Ketamine Therapy with Liver Disease: What's Safe (2026)

If you have liver disease and you're considering ketamine therapy, the honest summary upfront: most patients with stable liver disease can do at-home ketamine safely, with the same screening and monitoring a non-liver patient gets. The few patients who actually need to defer or shift to in-clinic care are a small group, and the reasons are predictable.

This post is the version of the conversation I have with patients at intake when liver disease shows up on the medical history. What matters, what doesn't, what your prescribing physician needs to see in labs, and where the actual line is between "yes with the standard protocol," "yes with adjustments," and "not at home."

How ketamine moves through your liver

Ketamine is metabolized primarily in the liver by the CYP3A4 and CYP2B6 enzyme systems. The major metabolite, norketamine, is also pharmacologically active and contributes to the antidepressant effect. Both eventually get cleared via the kidneys.

The clinical implication of liver-based metabolism: if your liver clears drugs more slowly than average, ketamine and norketamine stay in your system longer. That means a given dose produces a longer experience and slower return to baseline. For most patients with mild to moderate liver disease this doesn't change therapeutic effectiveness, but it does inform dosing decisions and session timing.

Sublingual at-home ketamine has one structural advantage here: it partially bypasses first-pass liver metabolism compared to oral routes (~25-32% bioavailability versus ~17% for swallowed). That means the liver does less of the initial processing work for the dose that actually reaches your bloodstream. For patients with compromised liver function, that's the right route by default.

The lab work your physician needs to see

A standard liver panel (ALT, AST, alkaline phosphatase, total bilirubin, INR, and albumin) drawn within the last 6 months tells your prescribing physician most of what they need to know. For some patients, this can be ordered at the same time the patient signs up; for others (especially those without a recent primary-care visit), it's an early step before any prescription is issued.

What we're looking for:

• ALT/AST elevated but stable, mild range (less than 2-3× upper limit of normal) — generally fine to proceed with standard protocol. Common in fatty liver disease and well-controlled hepatitis.
• Markedly elevated transaminases (more than 3-5× upper limit, or rising trend) — needs gastroenterology workup before starting. The question becomes "what's causing the elevation?" before adding any new drug to the picture.
• Bilirubin and albumin normal — good marker of synthetic liver function. Reassuring.
• INR normal or near-normal — synthetic function plus no significant clotting concern.
• Markedly elevated bilirubin or low albumin — suggests decompensated function and shifts the conversation toward in-clinic care or deferral.

If you have liver disease and don't have recent labs, getting them is the practical first step. Your primary care physician can order the panel, or DK can coordinate it with your local lab if there's no PCP relationship.

What's typically safe at home

The patient profiles I see comfortably do at-home ketamine therapy:

• Fatty liver disease (NAFLD or NASH, recently re-termed steatotic liver disease) with stable, mildly elevated transaminases — this is the most common scenario. Becoming more common in 2026 because of how prevalent it is. Generally a yes with standard protocol if labs are stable and bilirubin/albumin are normal.
• Treated and cured hepatitis C — once the virus is cleared and labs are stable, candidacy is the same as a non-hepatitis patient.
• Chronic hepatitis B on suppressive therapy with normal or near-normal labs — generally a yes.
• Mild alcoholic liver disease with active sobriety and stable labs — a yes, but the underlying alcohol-use story matters and is screened separately. Active alcohol use disorder is its own concern (see below).
• History of liver disease that resolved — current normal labs, the prior history doesn't change candidacy on its own.
• Compensated cirrhosis (Child-Pugh class A) — typically yes with dose adjustment and a longer follow-up cadence. The starting dose is often lower (50-75% of standard) and titrated up only if response is inadequate and labs stay stable.

For all of these groups, the practical protocol is identical to non-liver patients: standard sublingual dosing, peer supervisor present, eye mask, calm setting, 4-to-8-week induction, then maintenance. The only differences are baseline labs before starting and a check-in lab pull 4-6 weeks into treatment for the compensated-cirrhosis group.

When at-home ketamine is not the right fit

A short list of situations where I either defer or redirect patients with liver disease:

• Decompensated cirrhosis (Child-Pugh class B or C) — ascites, hepatic encephalopathy, variceal bleeding, jaundice, or poor synthetic function. These patients need treatment under specialty supervision rather than at-home protocols. Ketamine isn't structurally contraindicated, but the monitoring burden and risk of unexpected reactions warrants in-clinic delivery and a hepatologist in the loop.
• Active alcohol use disorder with liver disease — the combination is a hard pause. Both for safety reasons (alcohol plus ketamine plus compromised liver = stacked CNS and hepatic risk) and for therapeutic reasons (active substance use undermines ketamine's antidepressant effect). The right sequence is alcohol cessation first, stabilization of liver labs, then re-evaluation for ketamine.
• Acute hepatitis or rising transaminase trend — investigate the cause before adding any new drug. Once the underlying cause is identified and managed, candidacy can be reassessed.
• Liver transplant within the last 6 months — too soon to add another hepatically-metabolized drug to a regimen that includes immunosuppressants whose levels are highly sensitive to other liver-cleared agents. Coordination with the transplant team is mandatory; usually a defer.
• Active hepatocellular carcinoma in workup or active treatment — defer until the oncology pathway is settled.

These are honest stops, not box-checking. Every one of them is a situation where the risk-benefit calculation either tips toward deferring ketamine entirely or toward delivering it in a clinical setting with more monitoring than at-home allows.

Medications that complicate the picture

Beyond ketamine itself, the medication list matters when there's liver disease in play:

• Acetaminophen (Tylenol) — overuse for chronic pain in patients with existing liver disease is one of the most common preventable causes of further liver injury. We screen the entire pain-medication picture at intake and counsel on safer alternatives if Tylenol use is high.
• Statins — generally safe with mild liver enzyme elevation, but the combination with ketamine doesn't pose a new interaction issue. Continue as prescribed.
• Hepatitis treatments — direct-acting antivirals for HCV are largely cleared, no significant interaction with ketamine.
• Methotrexate or other hepatotoxic agents — flag for the physician; the broader medication-safety review applies.
• GLP-1 agonists (Ozempic, Mounjaro, Wegovy, Zepbound) — increasingly used for fatty liver indication. No significant ketamine interaction, but the gastric-emptying delay matters for fasting protocols and nausea management. See our medication safety with ketamine guide for the broader medication-interaction picture.

The recreational-use cautionary note

There is a real, documented relationship between heavy long-term recreational ketamine use and biliary tract injury, including a syndrome called "ketamine-induced cholangiopathy" reported in people using multiple grams per day for months to years. This is a recreational-use pattern, not a therapeutic-use pattern.

At sublingual therapeutic doses spaced weekly or every other week as part of a structured at-home protocol, the cumulative ketamine exposure is orders of magnitude lower than the recreational pattern that produces biliary injury. Therapeutic-dose ketamine does not produce the same hepatotoxic or biliary risk profile. The literature is clear on this distinction.

If you have a history of heavy recreational ketamine use (especially with imaging or labs suggesting prior biliary injury), that history needs to be on the intake form. Candidacy isn't automatically a no, but the workup and dosing pathway shift.

What changes for patients on the borderline

For patients who fall in the "yes with adjustments" range — typically compensated cirrhosis, fatty liver with moderately elevated transaminases, or treated hepatitis with imperfect lab normalization — the protocol differences are modest but real:

• Starting dose 50-75% of standard. Titrate up only if response is inadequate and labs stay stable.
• Longer session-to-session intervals during induction. Standard induction is 1-2 sessions per week for 4-8 weeks; for borderline-liver patients we typically start at every-other-week and only move to weekly if the patient tolerates it.
• Lab re-check at 4-6 weeks. A repeat liver panel to confirm no rise in transaminases attributable to treatment.
• Lower nausea threshold — borderline-liver patients have a slightly higher rate of session-day nausea. We address this proactively with hydration and timing (no large meal before the session).
• No alcohol on session days or for 48 hours after. This applies to all ketamine patients but is non-negotiable for the liver-disease subset.

These are small adjustments to the standard protocol. The treatment works the same way; the safety margin just gets a wider buffer.

Frequently Asked Questions

Is ketamine safe if you have liver problems?

For most patients with mild to moderate liver disease, yes. Stable fatty liver disease (NAFLD/NASH), cured hepatitis C, treated hepatitis B, and compensated cirrhosis (Child-Pugh A) are generally compatible with at-home ketamine therapy when liver function tests are reviewed first and a peer supervisor is present during sessions. Decompensated cirrhosis, active hepatitis, and recent liver transplant are reasons to defer or shift to in-clinic care.

Can you do ketamine with fatty liver disease (NAFLD/NASH)?

Yes, in most cases. Stable fatty liver with mildly elevated transaminases (less than 2-3× upper limit of normal) and normal bilirubin/albumin is fully compatible with at-home ketamine. The combination is increasingly common in 2026 because of how prevalent NAFLD has become. Your prescribing physician will want recent liver labs (LFT panel within the last 6 months) before starting.

Is chronic liver disease a hard stop for telehealth ketamine?

No. The hard-stop conditions are decompensated cirrhosis (Child-Pugh B or C, ascites, encephalopathy, variceal bleeding), active alcohol use disorder with liver disease, acute hepatitis with rising transaminases, or liver transplant within the last 6 months. Compensated chronic liver disease with stable labs is generally a yes with dose adjustment and lab monitoring.

Is ketamine safe in liver failure?

No, decompensated liver failure (Child-Pugh class C, hepatic encephalopathy, severely impaired synthetic function) is a reason to defer ketamine until the underlying liver disease is addressed. The metabolism of ketamine depends on hepatic enzymes that are significantly impaired in liver failure, which can lead to unpredictable drug levels and prolonged effects. Patients in this group need treatment under specialty hepatology supervision rather than at-home protocols.

Does ketamine cause liver damage?

At therapeutic doses, no. The hepatotoxicity concern with ketamine comes specifically from heavy recreational use (multiple grams per day for months to years), which has been associated with biliary tract injury called "ketamine-induced cholangiopathy." Sublingual therapeutic doses spaced weekly or every-other-week produce orders-of-magnitude lower cumulative exposure and do not carry the same risk profile.

What liver labs does my doctor need before starting ketamine?

A standard liver panel within the last 6 months: ALT, AST, alkaline phosphatase, total bilirubin, INR, and albumin. The transaminases (ALT/AST) tell us about ongoing inflammation; the bilirubin/INR/albumin tell us about synthetic function. If you don't have recent labs, your primary care physician can order them, or DK can coordinate with your local lab.

Can I take ketamine with hepatitis B or C?

Treated and cured hepatitis C (sustained virologic response after direct-acting antivirals) is fully compatible with at-home ketamine; candidacy is the same as a non-hepatitis patient. Chronic hepatitis B on suppressive therapy with stable labs is generally a yes. Active untreated hepatitis with rising transaminases needs investigation and treatment before adding ketamine to the picture.

Will I need lower doses if I have liver disease?

For most patients with stable mild-to-moderate liver disease, standard sublingual dosing is fine. For patients in the borderline range (compensated cirrhosis, moderately elevated transaminases), we typically start at 50-75% of the standard dose and titrate up only if response is inadequate and follow-up labs remain stable. Sublingual administration partially bypasses first-pass liver metabolism, which is one reason it's the preferred route for liver-disease patients.

Does alcohol use change the picture?

Significantly, yes. Active alcohol use disorder combined with liver disease is one of the clearer reasons to defer at-home ketamine. Alcohol plus ketamine plus compromised liver function stacks CNS and hepatic risk in ways that can't be safely managed at home, and active alcohol use undermines the antidepressant response. The right sequence is alcohol cessation first, stabilization of liver labs, then re-evaluation for ketamine therapy.

Ready to See Where You Stand?

If you have liver disease and want to know whether at-home ketamine therapy is right for your specific situation, I'm here to take a look. Dr. Ben Soffer is a board-certified physician with internal medicine training; liver function evaluation is core to that work. Every intake includes a review of your liver history and most-recent labs before any prescription is issued.

For the cardiovascular side of the comorbidity picture, see ketamine therapy with high blood pressure and ketamine therapy with heart disease. For the broader candidacy framework, see 12 ketamine contraindications. For Spravato as an alternative, see Spravato 2026 update.

The five-minute eligibility check will give you a quick read on whether your situation fits the at-home protocol or warrants a different pathway.